265 related articles for article (PubMed ID: 23898124)
1. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
3. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
6. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
[TBL] [Abstract][Full Text] [Related]
8. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
9. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Vincenzi B; Silletta M; Schiavon G; Frezza AM; Del Vescovo R; Zobel BB; Santini D; Dei Tos AP; Tonini G
Expert Opin Investig Drugs; 2013 Jan; 22(1):1-7. PubMed ID: 23157681
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
[TBL] [Abstract][Full Text] [Related]
16. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Tuettenberg J; Grobholz R; Korn T; Wenz F; Erber R; Vajkoczy P
J Cancer Res Clin Oncol; 2005 Jan; 131(1):31-40. PubMed ID: 15565458
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Hottinger AF; Ben Aissa A; Espeli V; Squiban D; Dunkel N; Vargas MI; Hundsberger T; Mach N; Schaller K; Weber DC; Bodmer A; Dietrich PY
Br J Cancer; 2014 May; 110(11):2655-61. PubMed ID: 24786603
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
20. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]